Radius IPO to raise up to $68.3m to support Phase III osteoporosis trials
This article was originally published in Scrip
Radius Health has set a preliminary price range of $8.50 to $10.50 per share for its initial public offering, which would raise $55.3-$68.3 million through the sale of 6.5 million shares to finance the development of the Cambridge, Massachusetts-based company's osteoporosis drugs.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.